Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 6/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.44 |
| ▸ | CASP7 | P55210 | 5/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CASP4 | P49662 | 1/20 | 0.44 |
| ▸ | CASP5 | P51878 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7991455 | 0.79 | ALDH1A1 (0.59) | ALDH1A1KDM4ETAAR1HRH1USP2 | |
| SCHEMBL2739054 | 0.79 | ALDH1A1 (0.59) | ALDH1A1KDM4ETAAR1HRH1USP2 | |
| SCHEMBL573579 | 0.79 | KDM4E (0.59) | ALDH1A1KDM4ETAAR1HRH1USP2 | |
| SCHEMBL25255051 | 0.79 | ALDH1A1 (0.59) | ALDH1A1KDM4ETAAR1HRH1USP2 | |
| SCHEMBL4476809 | 0.79 | KDM4E (0.59) | ALDH1A1KDM4ETAAR1HRH1USP2 | |
| SCHEMBL3668289 | 0.79 | ALDH1A1 (0.59) | ALDH1A1KDM4ETAAR1HRH1USP2 | |
| SCHEMBL5102919 | 0.79 | ALDH1A1 (0.59) | ALDH1A1KDM4ETAAR1HRH1USP2 | |
| SCHEMBL2274356 | 0.79 | ALDH1A1 (0.59) | ALDH1A1KDM4ETAAR1HRH1USP2 | |
| SCHEMBL16654217 | 0.79 | TAAR1 (0.57) | ALDH1A1KDM4ETAAR1HRH1USP2 | |
| Hydrochloric Acid SCHEMBL25310447 | 0.78 | ALDH1A1 (0.62) | ALDH1A1KDM4ETAAR1HRH1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114761406-B | Hydropyrido [1,2-a ] pyrazine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2024-04-19 | — | — | CN | claimed |
| EP-4069693-B1 | HYDROPYRIDO[1,2-ALPHA]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | HOFFMANN LA ROCHE (CH) | 2024-03-20 | — | — | EP | claimed |
| US-20230022297-A1 | HYDROPYRIDO[1,2-a]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | claimed |
| CN-114761406-A | Hydropyrido [1,2-a ] pyrazine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2022-07-15 | — | — | CN | claimed |
| WO-2021110614-A1 | HYDROPYRIDO[1,2-α]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2021-06-10 | — | — | WO | claimed |
| CN-114761406-B | Hydropyrido [1,2-a ] pyrazine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-4069693-B1 | HYDROPYRIDO[1,2-ALPHA]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | HOFFMANN LA ROCHE (CH) | 2024-03-20 | — | — | EP | disclosed |
| US-20230022297-A1 | HYDROPYRIDO[1,2-a]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
| CN-114761406-A | Hydropyrido [1,2-a ] pyrazine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2022-07-15 | — | — | CN | disclosed |
| WO-2021110614-A1 | HYDROPYRIDO[1,2-α]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022297-A1 | HYDROPYRIDO[1,2-a]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | TLR7, TLR9, TLR5 | ALDH1A1 2057/4885KDM4E 2893/4885TAAR1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.